Citius Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Citius Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$197.78 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Citius Pharmaceuticals Inc had its IPO on 2017-07-06 under the ticker symbol CTXR.

The company operates in the Healthcare sector and Biotechnology industry. Citius Pharmaceuticals Inc has a staff strength of 21 employees.

Stock update

Shares of Citius Pharmaceuticals Inc opened at $1.25 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $1.22 - $1.32, and closed at $1.32.

This is a +6.45% increase from the previous day's closing price.

A total volume of 1,600,602 shares were traded at the close of the day’s session.

In the last one week, shares of Citius Pharmaceuticals Inc have increased by +18.92%.

Citius Pharmaceuticals Inc's Key Ratios

Citius Pharmaceuticals Inc has a market cap of $197.78 million, indicating a price to book ratio of 1.5048 and a price to sales ratio of 0.

In the last 12-months Citius Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-34398480. The EBITDA ratio measures Citius Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Citius Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -18.53% with a return of equity of -29.5%.

In Q1, Citius Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Citius Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.25 per share while it has a forward price to earnings multiple of 1.2887 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Citius Pharmaceuticals Inc’s profitability.

Citius Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.8708. Its price to sales ratio in the trailing 12-months stood at 0.

Citius Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$104.24 million
Total Liabilities
$6.21 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Citius Pharmaceuticals Inc ended 2023 with $104.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $104.24 million while shareholder equity stood at $91.21 million.

Citius Pharmaceuticals Inc ended 2023 with $5.85 million in deferred long-term liabilities, $6.21 million in other current liabilities, 146358.00 in common stock, $-143808137.00 in retained earnings and $9.35 million in goodwill. Its cash balance stood at $29.07 million and cash and short-term investments were $29.07 million. The company’s total short-term debt was $207,471 while long-term debt stood at $0.

Citius Pharmaceuticals Inc’s total current assets stands at $34.90 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.73 million and inventory worth $0.

In 2023, Citius Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Citius Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Citius Pharmaceuticals Inc stock is currently trading at $1.32 per share. It touched a 52-week high of $1.71 and a 52-week low of $1.71. Analysts tracking the stock have a 12-month average target price of $6.

Its 50-day moving average was $1.31 and 200-day moving average was $1.19 The short ratio stood at 5.33 indicating a short percent outstanding of 0%.

Around 841.5% of the company’s stock are held by insiders while 1148.1% are held by institutions.

Frequently Asked Questions About Citius Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Citius Pharmaceuticals Inc is CTXR

The IPO of Citius Pharmaceuticals Inc took place on 2017-07-06

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.


11 Commerce Drive, Cranford, NJ, United States, 07016